$66.9 M

KBLB Mkt cap, 10-Nov-2021
Kraig Biocraft Laboratories Net income (FY, 2020)-5 M
Kraig Biocraft Laboratories EBIT (FY, 2020)-4.5 M
Kraig Biocraft Laboratories Cash, 31-Dec-2020816.9 K
Kraig Biocraft Laboratories EV68.4 M
Get notified regarding key financial metrics and revenue changes at Kraig Biocraft LaboratoriesLearn more
Banner background

Kraig Biocraft Laboratories Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

31.9k97.3k401.6k

Sales and marketing expense

R&D expense

250.6k465.3k489.4k439.5k432.0k397.1k258.9k148.1k223.1k88.5k

General and administrative expense

786.9k379.3k1.4m896.1k920.9k1.7m1.2m515.9k1.4m3.5m

Operating expense total

1.0m844.6k1.9m1.3m1.4m2.1m1.5m663.9k1.6m3.6m

EBIT

(1.3m)(1.2m)(2.3m)(1.8m)(2.1m)(2.9m)(2.2m)(959.9k)(2.6m)(4.5m)

EBIT margin, %

(9246%)(2215%)(239%)

Interest expense

2.1k45.7k177.1k209.0k

Interest income

192.047.06.4k

Pre tax profit

(1.3m)(7.5m)(1.9m)(2.1m)(3.1m)(2.3m)(1.2m)(2.9m)(5.0m)

Income tax expense

Net Income

(1.3m)(1.2m)(7.5m)(1.9m)(2.1m)(3.1m)(2.3m)(1.2m)(2.9m)(5.0m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

18.7k27.2k108.6k152.2k140.8k

Sales and marketing expense

R&D expense

140.9k210.0k145.4k155.3k164.8k96.4k116.1k108.1k68.8k79.6k143.5k90.7k110.7k139.9k129.3k114.2k51.4k25.4k20.1k50.9k20.2k22.3k20.9k44.0k4.8k33.0k

General and administrative expense

141.5k251.6k60.8k230.2k67.2k27.5k33.3k772.5k452.9k342.5k31.3k156.5k643.1k55.0k117.9k106.8k821.7k151.6k904.9k65.3k181.7k99.3k123.7k118.0k122.2k826.6k2.8m348.3k

Operating expense total

282.4k251.6k60.8k440.2k212.6k182.8k198.1k868.9k568.9k450.6k100.1k236.1k786.6k145.6k228.5k246.7k950.9k265.8k956.3k90.7k201.8k150.2k143.9k140.3k143.1k870.6k2.8m381.2k

EBIT

(337.8k)(325.2k)(138.1k)(501.8k)(276.9k)(258.7k)(285.6k)(940.9k)(652.4k)(545.7k)(222.0k)(404.0k)(943.5k)(322.8k)(477.9k)(500.7k)(1.1m)(454.5k)(1.2m)(234.4k)(226.6k)(152.9k)(147.9k)(412.0k)(335.2k)(1.1m)(3.0m)(470.3k)

EBIT margin, %

(5833%)(861%)(209%)(100%)(105%)

Interest expense

15.0k15.6k17.4k9.2k2.1k18.3k17.1k24.8k25.7k27.4k35.3k43.8k45.4k52.4k35.7k59.0k65.7k67.3k71.6k

Interest income

45.055.046.047.01.2k3.4k1.6k

Pre tax profit

(335.7k)(325.2k)(138.0k)(513.8k)(292.5k)(303.0k)(950.1k)(650.3k)(564.0k)(239.0k)(416.2k)(968.3k)(348.5k)(509.0k)(528.1k)(1.1m)(494.6k)(1.3m)(279.8k)(278.9k)(188.6k)(207.0k)(477.7k)(402.5k)(1.1m)(3.1m)(568.8k)

Income tax expense

Net Income

(335.7k)(325.2k)(138.0k)(513.8k)(292.5k)(275.3k)(303.0k)(950.1k)(650.3k)(564.0k)(239.0k)(416.2k)(968.3k)(348.5k)(509.0k)(528.1k)(1.1m)(494.6k)(1.3m)(279.8k)(278.9k)(188.6k)(207.0k)(477.7k)(402.5k)(1.1m)(3.1m)(568.8k)

Kraig Biocraft Laboratories Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

98.5k121.3k277.2k253.9k136.3k134.6k123.8k179.7k539.2k543.2k726.9k249.3k102.8k220.7k187.0k106.9k335.9k253.9k228.8k74.4k48.5k34.4k22.3k907.7k674.2k283.1k37.4k54.7k

Accounts Receivable

18.7k27.2k41.0k114.0k99.3k

Prepaid Expenses

4.0k1.0k4.5k1.6k1.2k1.4k1.7k26.4k1.0k1.0k250.0250.02.4k1.9k787.0250.06.8k4.5k4.5k1.4k5.1k35.2k12.7k12.7k8.5k

Current Assets

98.5k121.3k283.2k264.0k143.5k145.3k125.3k180.9k540.5k544.9k753.2k250.3k103.8k220.9k187.3k109.3k356.4k254.6k229.0k108.4k94.0k152.9k123.0k912.8k709.5k295.8k50.1k63.2k

PP&E

23.6k22.3k20.7k19.3k17.9k15.1k13.7k15.7k12.5k11.0k9.4k79.8k74.6k70.3k61.9k57.7k56.0k48.7k62.1k61.7k62.4k57.0k54.1k40.6k33.9k97.8k109.9k104.2k

Total Assets

122.1k143.6k303.9k283.3k161.4k160.5k139.1k196.6k553.1k555.9k762.6k330.1k178.4k291.3k249.2k167.0k412.4k303.4k291.1k170.1k159.9k213.4k180.6k1.1m1.3m898.6k608.1k586.2k

Accounts Payable

489.0k505.9k214.7k316.7k357.2k468.2k405.2k451.1k432.9k470.0k533.6k547.1k583.5k533.4k488.6k519.6k617.7k581.4k606.6k663.3k697.2k697.7k323.6k320.0k342.5k482.4k488.5k

Short-term debt

65.3k65.3k50.0k50.0k50.0k50.0k195.0k245.0k265.0k442.0k442.0k442.0k1.1m1.4m

Current Liabilities

840.9k1.1m1.2m920.4k1.1m1.5m1.6m1.4m1.6m1.5m1.6m1.9m2.0m2.1m2.4m2.5m2.7m3.0m3.1m3.2m3.7m4.0m4.1m4.4m4.7m4.9m6.0m6.4m

Long-term debt

115.2k426.1k398.3k509.8k463.7k

Total Debt

65.3k65.3k50.0k50.0k50.0k50.0k195.0k245.0k265.0k557.2k868.1k840.3k1.6m1.8m

Total Liabilities

856.0k1.1m1.2m931.6k1.1m1.5m1.6m1.4m2.4m2.5m2.7m3.0m3.1m4.8m5.3m5.5m6.5m6.9m

Common Stock

22.0k22.0k22.0k6.3m6.3m6.5m6.6m7.5m9.0m9.4m9.8m10.0m10.1m10.5m11.0m12.3m12.7m13.4m13.7m14.3m15.1m15.1m15.1m16.4m

Preferred Stock

5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m5.2m

Additional Paid-in Capital

920.3k920.3k920.3k920.3k920.3k1.3m920.3k1.7m1.7m1.9m1.9m1.8m2.4m2.4m2.4m1.4m2.2m2.6m2.8m2.8m2.0m2.0m2.0m2.0m2.0m2.3m5.0m5.1m

Retained Earnings

(18.6m)(19.6m)(19.9m)(20.8m)(21.3m)(22.5m)(23.9m)(25.1m)(25.4m)(26.0m)(26.2m)(26.4m)(27.4m)(27.8m)(28.9m)(32.8m)(33.4m)

Total Equity

(733.9k)(959.1k)(944.5k)(648.3k)(940.9k)(1.3m)(1.5m)(1.2m)(1.0m)(976.6k)(815.6k)(1.6m)(1.8m)(1.8m)(2.1m)(2.4m)(2.3m)(2.7m)(2.8m)(3.1m)(3.6m)(3.8m)(4.0m)(3.7m)(4.1m)(4.6m)(5.9m)(6.3m)

Debt to Equity Ratio

-0.1 x-0.1 x0 x0 x0 x0 x-0.1 x-0.1 x-0.1 x-0.2 x-0.2 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.2 x0.2 x0.3 x1.2 x1.1 x1.5 x0.5 x0.7 x

Financial Leverage

-0.2 x-0.1 x-0.3 x-0.4 x-0.2 x-0.1 x-0.1 x-0.2 x-0.5 x-0.6 x-0.9 x-0.2 x-0.1 x-0.2 x-0.1 x-0.1 x-0.2 x-0.1 x-0.1 x-0.1 x0 x-0.1 x0 x-0.3 x-0.3 x-0.2 x-0.1 x-0.1 x

Kraig Biocraft Laboratories Cash Flow

Annual

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(580.7k)(905.9k)(138.0k)(651.8k)(944.4k)(275.3k)(578.3k)(1.5m)(650.3k)(1.2m)(1.5m)(416.2k)(1.4m)(1.7m)(509.0k)(1.0m)(2.2m)(494.6k)(1.8m)(2.0m)(278.9k)(467.5k)(674.5k)(477.7k)(880.2k)(2.0m)(3.1m)(3.6m)

Depreciation and Amortization

2.7k4.0k1.4k2.8k4.2k1.4k2.8k4.3k1.5k3.1k4.7k2.6k6.9k11.2k4.2k8.4k12.6k4.3k8.7k14.1k6.4k13.0k19.8k6.7k13.4k22.4k7.4k13.1k

Accounts Receivable

18.7k31.9k31.9k4.6k(15.1k)(88.1k)(73.4k)

Accounts Payable

58.5k250.1k24.3k(266.8k)(164.8k)28.0k139.0k77.8k110.6k70.5k107.5k21.0k34.5k71.0k63.6k24.8k44.3k104.1k67.8k93.1k(14.8k)40.0k40.5k76.0k73.4k95.9k(78.5k)(72.4k)

Cash From Operating Activities

(361.7k)(438.3k)(17.2k)(339.2k)(456.1k)(168.5k)(309.5k)(592.3k)(155.1k)(500.4k)(715.6k)(206.5k)(502.9k)(685.1k)(251.2k)(606.3k)(824.8k)(193.6k)(500.9k)(650.3k)(78.4k)(141.2k)(169.4k)(225.0k)(455.5k)(769.6k)(372.6k)(697.9k)

Purchases of PP&E

(3.5k)(39.3k)(39.3k)(39.3k)(2.5k)(1.4k)(19.2k)(24.2k)(6.3k)(7.6k)(11.4k)(73.0k)

Cash From Investing Activities

(45.0)(100.0)(145.0)(46.0)6.1k(3.5k)(39.3k)(39.3k)(39.3k)(2.5k)(1.4k)(19.2k)(24.2k)(6.3k)(7.6k)(11.4k)(73.0k)

Long-term Borrowings

(1.0k)(4.0k)(8.0k)(15.0k)(30.0k)

Cash From Financing Activities

368.0k467.4k99.1k397.8k397.2k249.3k373.3k721.7k398.9k748.2k1.1m150.0k450.0k200.0k475.0k925.0k150.0k450.0k450.0k115.0k165.0k185.0k1.1m1.1m1.1m285.0k627.6k

Net Change in Cash

6.3k29.1k81.8k58.5k(59.1k)80.8k70.0k125.9k243.8k247.8k431.5k(245.8k)(392.2k)(274.4k)(51.2k)(131.3k)97.7k(45.0k)(70.1k)(224.4k)30.4k16.3k4.2k894.0k660.5k269.5k(87.6k)(70.3k)

Interest Paid

Income Taxes Paid

Kraig Biocraft Laboratories Ratios

USDQ2, 2011

Financial Leverage

-0.2 x